These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 24138435)

  • 1. A Bayesian design space for analytical methods based on multivariate models and predictions.
    Lebrun P; Boulanger B; Debrus B; Lambert P; Hubert P
    J Biopharm Stat; 2013; 23(6):1330-51. PubMed ID: 24138435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A quality by design approach for longitudinal quality attributes.
    Lebrun P; Giacoletti K; Scherder T; Rozet E; Boulanger B
    J Biopharm Stat; 2015; 25(2):247-59. PubMed ID: 25360720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analytical procedure validation and the quality by design paradigm.
    Rozet E; Lebrun P; Michiels JF; Sondag P; Scherder T; Boulanger B
    J Biopharm Stat; 2015; 25(2):260-8. PubMed ID: 25357001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design space approach in the optimization of the spray-drying process.
    Lebrun P; Krier F; Mantanus J; Grohganz H; Yang M; Rozet E; Boulanger B; Evrard B; Rantanen J; Hubert P
    Eur J Pharm Biopharm; 2012 Jan; 80(1):226-34. PubMed ID: 21983606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Bayesian approach to the ICH Q8 definition of design space.
    Peterson JJ
    J Biopharm Stat; 2008; 18(5):959-75. PubMed ID: 18781528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of a stability-indicating method by Quality-by-Design versus Quality-by-Testing: a case of a learning process.
    Hubert C; Lebrun P; Houari S; Ziemons E; Rozet E; Hubert P
    J Pharm Biomed Anal; 2014 Jan; 88():401-9. PubMed ID: 24176744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bayesian approach for quantifying the uncertainty of neutron doses derived from spectrometric measurements.
    Reginatto M
    Radiat Prot Dosimetry; 2006; 121(1):64-9. PubMed ID: 16877470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical methods for bridging studies.
    Chow SC; Chiang C; Liu JP; Hsiao CF
    J Biopharm Stat; 2012 Sep; 22(5):903-15. PubMed ID: 22946939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluating the reliability of analytical results using a probability criterion: a Bayesian perspective.
    Rozet E; Govaerts B; Lebrun P; Michail K; Ziemons E; Wintersteiger R; Rudaz S; Boulanger B; Hubert P
    Anal Chim Acta; 2011 Oct; 705(1-2):193-206. PubMed ID: 21962362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of new methodologies based on design of experiments, independent component analysis and design space for robust optimization in liquid chromatography.
    Debrus B; Lebrun P; Ceccato A; Caliaro G; Rozet E; Nistor I; Oprean R; Rupérez FJ; Barbas C; Boulanger B; Hubert P
    Anal Chim Acta; 2011 Apr; 691(1-2):33-42. PubMed ID: 21458628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Experimental designs and their recent advances in set-up, data interpretation, and analytical applications.
    Dejaegher B; Heyden YV
    J Pharm Biomed Anal; 2011 Sep; 56(2):141-58. PubMed ID: 21632194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Bayesian-frequentist two-stage single-arm phase II clinical trial design.
    Dong G; Shih WJ; Moore D; Quan H; Marcella S
    Stat Med; 2012 Aug; 31(19):2055-67. PubMed ID: 22415966
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bayesian predictive two-stage design for phase II clinical trials.
    Sambucini V
    Stat Med; 2008 Apr; 27(8):1199-224. PubMed ID: 17763528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bayesian approach to noninferiority trials for proportions.
    Gamalo MA; Wu R; Tiwari RC
    J Biopharm Stat; 2011 Sep; 21(5):902-19. PubMed ID: 21830922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of a Saccharomyces cerevisiae fermentation process for production of a therapeutic recombinant protein using a multivariate Bayesian approach.
    Fu Z; Leighton J; Cheng A; Appelbaum E; Aon JC
    Biotechnol Prog; 2012 Jul; 28(4):1095-105. PubMed ID: 22581591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A fully Bayesian multivariate approach to before-after safety evaluation.
    Park ES; Park J; Lomax TJ
    Accid Anal Prev; 2010 Jul; 42(4):1118-27. PubMed ID: 20441821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A general and flexible approach to estimating the social relations model using Bayesian methods.
    Lüdtke O; Robitzsch A; Kenny DA; Trautwein U
    Psychol Methods; 2013 Mar; 18(1):101-19. PubMed ID: 22799626
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of an UPLC method for determination of content uniformity in low-dose solid drugs products using the design space approach.
    Oliva A; Fariña JB; Llabrés M
    Talanta; 2013 Oct; 115():490-9. PubMed ID: 24054623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian interim analysis in clinical trials.
    Zhang X; Cutter G
    Contemp Clin Trials; 2008 Sep; 29(5):751-5. PubMed ID: 18589003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testing simultaneous hypotheses in pharmaceutical trials: a Bayesian approach.
    Dominici F
    J Biopharm Stat; 1998 May; 8(2):283-97. PubMed ID: 9598423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.